Aesica has struck a deal with Australia's QRxPharma, agreeing to promote the company's abuse-deterrence technology to its clients manufacturing controlled drugs. Under the agreement, Aesica will pitch QRxPharma's Stealth Beadlets for inclusion in formulations of controlled substances, entering into fee-for-service deals with clients while QRxPharma negotiates licensing terms. More